Cancer Treatment with Immune Checkpoint Inhibitors in Kidney Recipients

Renal Transplantation and Cancer


Abstract views: 29 / PDF downloads: 20

Authors

DOI:

https://doi.org/10.5281/zenodo.11216023

Keywords:

Not Available

Abstract

Not Available

References

Berthoux F, Mariat C. Cardiovascular death after renal transplantation remains the first cause despite significant quantitative and qualitative changes. Transplantation. 2010 Apr 15;89(7):806. doi: 10.1097/TP.0b013e3181caeece. PMID: 20061998.

Pourmand G, Salem S, Mehrsai A, Taherimahmoudi M, Ebrahimi R, Pourmand MR. Infectious complications after kidney transplantation: a single-center experience. Transpl Infect Dis. 2007 Dec;9(4):302-9. doi: 10.1111/j.1399-3062.2007.00229.x. Epub 2007 May 19. PMID: 17511823.

Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007 Jul 7;370(9581):59-67. doi: 10.1016/S0140-6736(07)61050-2. PMID: 17617273.

Haslam A, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019 May 3;2(5):e192535. doi: 10.1001/jamanetworkopen.2019.2535. PMID: 31050774; PMCID: PMC6503493.

Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020 Jan 14;52(1):17-35. doi: 10.1016/j.immuni.2019.12.011. PMID: 31940268.

Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627-1639. doi:10.1056/NEJMoa1507643

Duni A, Kitsos A, Liapis G, Tatsis V, Pappas C, Dounousi E. Acute Kidney Transplant Rejection After Administration of Nivolumab in a Dialysis Patient With a Failed Graft. Kidney Int Rep. 2021 Mar 3;6(5):1459-1463. doi: 10.1016/j.ekir.2021.02.039. PMID: 34013126; PMCID: PMC8116751.

Murakami N, Mulvaney P, Danesh M, et al. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 2021;100(1):196-205. doi:10.1016/j.kint.2020.12.015

Published

2024-05-19

How to Cite

Elidrissi, M. K., & Ahmedi, M. Y. (2024). Cancer Treatment with Immune Checkpoint Inhibitors in Kidney Recipients: Renal Transplantation and Cancer. Journal of European Internal Medicine Professionals, 2(2). https://doi.org/10.5281/zenodo.11216023